Bonviva (Ibandronic Acid Sodium Monohydrate)

Adult administration

Administer 3 mg by intravenous injection once every 3 months over 15 - 30 seconds.

This medication must be administered intravenously. Caution is required as injection into arteries or around veins can cause tissue damage. This medication should not be used in patients with allergy to the drug or its components, or in patients with untreated hypocalcemia. During treatment, side effects such as indigestion, abdominal pain, nausea, headache, rash, myalgia, and arthralgia may occur, but most are mild to moderate and do not warrant discontinuation of therapy. Occasionally, influenza-like symptoms such as fever, chills, fatigue, myalgia, and arthralgia may appear, but these symptoms generally resolve naturally within a short period. Prolonged use of this drug may rarely cause osteonecrosis of the jaw or bones surrounding the ear; therefore, especially for cancer patients or those undergoing dental treatment, it is advisable to have an oral examination before administration. If dental treatment is necessary, excessive dental procedures should be avoided while taking this medication, and decisions about whether to discontinue treatment should be made in consultation with a specialist. This medication may temporarily lower serum calcium levels, so it is important to treat hypocalcemia or bone metabolic disorders before administration and ensure sufficient intake of calcium and vitamin D. Patients with impaired kidney function or who are taking medications affecting the kidneys require regular monitoring and observation. During administration of this medication, sudden allergic reactions or anaphylaxis may occur; therefore, it should be given in an environment where emergency treatment is available. Women who are pregnant or breastfeeding are advised not to use this medication due to the lack of established safety. Overdose may cause issues with the kidneys and liver; if an overdose is suspected, immediate consultation with medical personnel and appropriate treatment is required. This medication should not be mixed with other intravenous medications or calcium-containing solutions, and it must be administered using a separate intravenous line. After administration, monitor closely for any adverse reactions, and report any abnormal symptoms to medical personnel immediately.

Serious side effects

Urticaria, angioedema, facial swelling/edema, anaphylaxis reaction/shock (severe allergic reaction), Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis (severe skin adverse reaction), dyspnea, asthma exacerbation (breathing problems), skin peeling, multiple organ failure, death, acute renal failure, severe edema accompanied by high blood pressure, liver abnormalities (jaundice), severe neurological symptoms, severe allergic reactions

Mild side effects

• Gastritis
• diarrhea
• abdominal pain
• indigestion
• nausea
• constipation
• musculoskeletal pain
• arthralgia
• myalgia
• influenza-like illness

This medication should be stored in a sealed container to prevent exposure to air and moisture, and the storage temperature should be maintained at room temperature between 1 degree and 30 degrees Celsius. This helps to maintain the efficacy of the medication and prevent degradation.

Appearance

A colorless, transparent solution filled in a prefilled syringe with a single-use injection needle attached.

Package unit

1 prefilled syringe